An
artist's conception of nanodiamonds used for in vitro diagnostics. Courtesy: Ella
Maru Studio/ UCL
The
quantum sensing abilities of nanodiamonds can be used to improve the
sensitivity of paper-based diagnostic tests, potentially allowing for earlier
detection of diseases such as HIV, according to a study led by UCL researchers
in the i-sense McKendry group.
Paper-based
lateral flow tests work the same way as a pregnancy test in that a strip of
paper is soaked in a fluid sample and a change in colour—or fluorescent
signal—indicates a positive result and the detection of virus proteins or DNA.
They are widely used to detect viruses ranging from HIV to SARS-CoV-2 (lateral
flow tests for Covid-19 are currently being piloted across England) and can
provide a rapid diagnosis, as the results do not have to be processed in a lab.
The new
research, published in Nature, found that low-cost nanodiamonds could be used
to signal the presence of an HIV disease marker with a sensitivity many
thousands of times greater than the gold nanoparticles widely used in these
tests.
This
greater sensitivity allows lower viral loads to be detected, meaning the test
could pick up lower levels of disease or detect the disease at an earlier
stage, which is crucial for reducing transmission risk of infected individuals
and for effective treatment of diseases such as HIV.
The
research team are working on adapting the new technology to test for COVID-19
and other diseases over the coming months. A key next step is to develop a
hand-held device that can "read" the results, as the technique was
demonstrated using a microscope in a laboratory. Further clinical evaluation
studies are also planned.
Lead
author Professor Rachel McKendry, Professor of Biomedical Nanotechnology at UCL
and Director of i-sense EPSRC IRC, said: "Our proof-of-concept study shows
how quantum technologies can be used to detect ultralow levels of virus in a
patient sample, enabling much earlier diagnosis.
"We
have focused on the detection of HIV, but our approach is very flexible and can
be easily adapted to other diseases and biomarker types. We are working on
adapting our approach to COVID-19. We believe that this transformative new
technology will benefit patients and protect populations from infectious
diseases."
The
researchers made use of the quantum properties of nanodiamonds manufactured
with a precise imperfection. This defect in the highly regular structure of a
diamond creates what is called a nitrogen-vacancy (NV) centre. NV centres have
many potential applications, from fluorescent biomarking for use in
ultra-sensitive imaging to information processing qubits in quantum computing.
The NV
centres can signal the presence of an antigen or other target molecule by
emitting a bright fluorescent light. In the past, fluorescent markers have been
limited by background fluorescence, either from the sample or the test strip,
making it harder to detect low concentrations of virus proteins or DNA that
would indicate a positive test. However, the quantum properties of fluorescent
nanodiamonds allow their emission to be selectively modulated, meaning the
signal can be fixed at a set frequency using a microwave field and can be
efficiently separated from the background fluorescence, addressing this
limitation.
The
optical results showed up to a five orders of magnitude (100,000 times)
improvement in sensitivity compared to gold nanoparticles (that is, a much
lower number of nanoparticles were required to generate a detectable signal).
With the inclusion of a short 10-minute constant-temperature amplification
step, in which copies of the RNA were multiplied, the researchers were able to
detect HIV RNA at the level of a single molecule in a model sample.
The work
was demonstrated in a laboratory setting but the team hopes to develop the
tests so that the results could be read with a smartphone or portable
fluorescence reader. This means that the test could, in future, be performed in
low-resource settings, making it more accessible to users.
First
author Dr. Ben Miller (i-sense Postdoctoral Research Associate at the London
Centre for Nanotechnology at UCL) said: "Paper-based lateral flow tests
with gold nanoparticles do not require laboratory analysis, making them
particularly useful in low resource settings and where access to healthcare is
limited. They are low cost, portable, and user friendly.
"However,
these tests currently lack the sensitivity to detect very low levels of
biomarkers. By replacing commonly used gold nanoparticles with fluorescent
nanodiamonds in this new design, and selectively modulating their (already
bright) emission of light, we have been able to separate their signal from the
unwanted background fluorescence of the test strip, dramatically improving
sensitivity."
Co-author
Professor John Morton, Director of UCL's Quantum Science and Technology
Institute (UCLQ), said: "This interdisciplinary collaboration between UCLQ
and the i-sense team in the LCN is a fantastic illustration of how foundational
work on quantum systems, such as NV centre in diamond, can evolve from the lab
and play a crucial role in real-world applications in sensing and diagnostics.
Researchers at UCLQ are exploring and enabling the impact of these and other
quantum technologies by working with industry and other academic research
groups."